Lower risk of dementia and Alzhéimer: the last advantage that science points to from Ozempic

Researchers from the DeCo Chair for the early detection of cognitive impairment, created by the CEU Cardenal Herrera University (CEU UCH) and the Very Illustrated Official College of Pharmacists of Valencia (MICOF), have published a new study in the scientific journal Journal of Alzheimer’s Disease. The research analyzes the relationship between treatments for type 2 diabetes and biomarkers of Alzheimer’s disease in cerebrospinal fluid, in a stu…

In just a few years, Ozempic has gone from being a drug known only in endocrinology consultations to becoming a common name in public conversation. Its active substance, semaglutide, was designed to control type 2 diabetes, but soon demonstrated positive side effects, such as a noticeable reduction in body weight. This finding propitiated a wave of prescriptions also for obesity-related purposes, catapulting the drug to an international populari…